Evidence map›Paper›PMID 28326169›Full record

ArticleJournal of extracellular vesicles2017

Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet's disease severity.

Tamer Kahraman, Gozde Gucluler, Ismail Simsek, Fuat Cem Yagci, Muzaffer Yildirim, Can Ozen, Ayhan Dinc, Mayda Gursel, Lolai Ikromzoda, Tolga Sutlu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of extracellular vesicles, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Tamer KahramanScience Faculty, Department of Molecular Biology and Genetics, Bilkent University , Ankara , Turkey.
Gozde GuclulerScience Faculty, Department of Molecular Biology and Genetics, Bilkent University , Ankara , Turkey.
Ismail SimsekDivision of Rheumatology, Gulhane School of Medicine , Ankara , Turkey.
Fuat Cem YagciScience Faculty, Department of Molecular Biology and Genetics, Bilkent University , Ankara , Turkey.
Muzaffer YildirimScience Faculty, Department of Molecular Biology and Genetics, Bilkent University , Ankara , Turkey.
Can OzenDepartment of Biotechnology, Middle East Technical University , Ankara , Turkey.
Ayhan DincDivision of Rheumatology, Gulhane School of Medicine , Ankara , Turkey.
Mayda GurselDepartment of Biological Sciences, Middle East Technical University , Ankara , Turkey.
Lolai IkromzodaNanotechnology Research and Application Center, Sabanci University , Istanbul , Turkey.
Tolga SutluNanotechnology Research and Application Center, Sabanci University , Istanbul , Turkey.
Stephen GayDepartment of Rheumatology, University Hospital Zurich , Zurich , Switzerland.
Ihsan GurselScience Faculty, Department of Molecular Biology and Genetics, Bilkent University , Ankara , Turkey.
Bilkent University · TRGülhane Askerî Tıp Akademisi · TRMiddle East Technical University · TRSabancı Üniversitesi · TRUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behçet's disease (BD) activity is characterised by sustained, over-exuberant immune activation, yet the underlying mechanisms leading to active BD state are poorly defined. Herein, we show that the human cathelicidin derived antimicrobial peptide LL37 associates with and directs plasma extracellular vesicles (EV) to immune cells, thereby leading to enhanced immune activation aggravating BD pathology. Notably, disease activity was correlated with elevated levels of circulating LL37 and EV plasma concentration. Stimulation of healthy PBMC with active BD patient EVs induced heightened IL1β, IFNα, IL6 and IP10 secretion compared to healthy and inactive BD EVs. Remarkably, when mixed with LL37, healthy plasma-EVs triggered a robust immune activation replicating the pathology inducing properties of BD EVs. The findings of this study could be of clinical interest in the management of BD, implicating LL37/EV association as one of the major contributors of BD pathogenesis.

Indexed as

autoimmuneBehçet’s diseasecytokineExtracellular vesiclesimmune activationLL37

Identifiers

PMID28326169
PMCPMC5345581
OpenAlexW2592265539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.